CU23736A1 - Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso - Google Patents

Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Info

Publication number
CU23736A1
CU23736A1 CU20090071A CU20090071A CU23736A1 CU 23736 A1 CU23736 A1 CU 23736A1 CU 20090071 A CU20090071 A CU 20090071A CU 20090071 A CU20090071 A CU 20090071A CU 23736 A1 CU23736 A1 CU 23736A1
Authority
CU
Cuba
Prior art keywords
sulfated
monoclonal antibodies
fragments
present
proteoglycans
Prior art date
Application number
CU20090071A
Other languages
English (en)
Inventor
Navarro Victor Brito
Lopez Yosdel Soto
Marrero Yuniel Fernandez
Requena Alejandro Lopez
De Acosta Del Rio Cristina Maria Mateo
Lopez Ana Maria Vazquez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42355373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23736(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU20090071A priority Critical patent/CU23736A1/es
Priority to TW099111628A priority patent/TWI424852B/zh
Priority to PE2010000230A priority patent/PE20100808A1/es
Priority to CL2010000413A priority patent/CL2010000413A1/es
Priority to ARP100101450A priority patent/AR076495A1/es
Priority to KR1020117024741A priority patent/KR101374263B1/ko
Priority to HK12108917.9A priority patent/HK1168362B/xx
Priority to MYPI2011005199A priority patent/MY158954A/en
Priority to AU2010244859A priority patent/AU2010244859B2/en
Priority to JP2012508894A priority patent/JP5354823B2/ja
Priority to CA2758994A priority patent/CA2758994C/en
Priority to EP10721287.0A priority patent/EP2428521B1/en
Priority to US13/264,105 priority patent/US8470322B2/en
Priority to ES10721287.0T priority patent/ES2656849T3/es
Priority to MX2011011665A priority patent/MX2011011665A/es
Priority to PCT/CU2010/000002 priority patent/WO2010127642A1/es
Priority to SG2011080298A priority patent/SG175849A1/en
Priority to BRPI1013991-5A priority patent/BRPI1013991B1/pt
Priority to CN201080019730.6A priority patent/CN102414222B/zh
Priority to RU2011149252/10A priority patent/RU2502744C2/ru
Publication of CU23736A1 publication Critical patent/CU23736A1/es
Priority to ZA2011/08832A priority patent/ZA201108832B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención está relacionada con el campo de la biotecnologia y particularmente con nuevos productos para ser usados en la salud humana. La presente invención proporciona nuevos anticuerpos monoclonales que reconocen de manera específica y con alta afinidad sulfátidos y proteoglicanos sulfatados. Los agentes de unión a sulfátidos y proteoglicanos sulfatados de la invención descritos en la presente memoria descriptiva, proporcionan importantes agentes diagnósticos y terapéuticos para actuar sobre procesos patológicos asociados a la aparición de placas ateroscleróticas. Según esto, la invención proporciona composiciones farmacéuticas que comprenden los anticuerpos monoclonales de la invención a los fragmentos derivados de estos anticuerpos para su uso terapéutico y diagnostico asociado a enfermedades cardiovasculares. Adicionalmente la presente invención se relaciona con los fragmentos de los anticuerpos monoclonales que reconocen sulfátidos y proteoglicanos sulfatados, de modo que dichos fragmentos puedan ser usados en la terapia o el diagnostico de esta patología.
CU20090071A 2009-05-04 2009-05-04 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso CU23736A1 (es)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CU20090071A CU23736A1 (es) 2009-05-04 2009-05-04 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
TW099111628A TWI424852B (zh) 2009-05-04 2010-04-14 抗腦苷硫酸酯類且抗硫酸化蛋白聚糖類之抗體類及彼等之用途
PE2010000230A PE20100808A1 (es) 2009-05-04 2010-04-15 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados
CL2010000413A CL2010000413A1 (es) 2009-05-04 2010-04-26 Anticuerpo monoclonal que reconoce sulfatidos y proteoglicanos sulfatados; composicion farmaceutica que lo comprende; y sus usos para el diagnostico y tratamiento de aterosclerosis.
ARP100101450A AR076495A1 (es) 2009-05-04 2010-04-29 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
RU2011149252/10A RU2502744C2 (ru) 2009-05-04 2010-05-03 Антитела к сульфатидам и сульфатированным протеогликанам и их применение
CA2758994A CA2758994C (en) 2009-05-04 2010-05-03 Antibodies that recognize sulphatides and sulphated proteoglycans and the use thereof
MX2011011665A MX2011011665A (es) 2009-05-04 2010-05-03 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso.
MYPI2011005199A MY158954A (en) 2009-05-04 2010-05-03 Antibodies that recognize sulphatides and sulphated proteoglycans and the use
AU2010244859A AU2010244859B2 (en) 2009-05-04 2010-05-03 Antibodies that recognize sulphatides and sulphated proteoglycans and the use thereof
JP2012508894A JP5354823B2 (ja) 2009-05-04 2010-05-03 スルファチド及び硫酸化プロテオグリカンを認識する抗体並びにその使用
KR1020117024741A KR101374263B1 (ko) 2009-05-04 2010-05-03 항 황산염 및 항 항산화 프로테오글리칸 항체 및 이들의 용도
EP10721287.0A EP2428521B1 (en) 2009-05-04 2010-05-03 Anti sulfatides and anti sulfated proteoglycans antibodies and their use
US13/264,105 US8470322B2 (en) 2009-05-04 2010-05-03 Anti sulfatides and anti sufated proteoglycans antibodies and their use
ES10721287.0T ES2656849T3 (es) 2009-05-04 2010-05-03 Anticuerpos antisulfátidos y proteoglicanos antisulfatados y su uso
HK12108917.9A HK1168362B (en) 2009-05-04 2010-05-03 Antibodies that recognize sulphatides and sulphated proteoglycans and the use thereof
PCT/CU2010/000002 WO2010127642A1 (es) 2009-05-04 2010-05-03 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
SG2011080298A SG175849A1 (en) 2009-05-04 2010-05-03 Antibodies that recognize sulphatides and sulphated proteoglycans and the use thereof
BRPI1013991-5A BRPI1013991B1 (pt) 2009-05-04 2010-05-03 Anticorpo monoclonal, composição farmacêutica, conjunto de reativos úteis no diagnóstico de lesões ateroscleróticas, e, uso de um anticorpo
CN201080019730.6A CN102414222B (zh) 2009-05-04 2010-05-03 抗硫苷脂和抗硫酸化蛋白聚糖抗体及其用途
ZA2011/08832A ZA201108832B (en) 2009-05-04 2011-12-01 Antibodies that recognize sulphatides and sulphated proteoglycans and the use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090071A CU23736A1 (es) 2009-05-04 2009-05-04 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Publications (1)

Publication Number Publication Date
CU23736A1 true CU23736A1 (es) 2011-11-15

Family

ID=42355373

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090071A CU23736A1 (es) 2009-05-04 2009-05-04 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Country Status (20)

Country Link
US (1) US8470322B2 (es)
EP (1) EP2428521B1 (es)
JP (1) JP5354823B2 (es)
KR (1) KR101374263B1 (es)
CN (1) CN102414222B (es)
AR (1) AR076495A1 (es)
AU (1) AU2010244859B2 (es)
BR (1) BRPI1013991B1 (es)
CA (1) CA2758994C (es)
CL (1) CL2010000413A1 (es)
CU (1) CU23736A1 (es)
ES (1) ES2656849T3 (es)
MX (1) MX2011011665A (es)
MY (1) MY158954A (es)
PE (1) PE20100808A1 (es)
RU (1) RU2502744C2 (es)
SG (1) SG175849A1 (es)
TW (1) TWI424852B (es)
WO (1) WO2010127642A1 (es)
ZA (1) ZA201108832B (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US20020018808A1 (en) 1990-12-10 2002-02-14 Alving Carl R. Vaccines against sterols
US5541296A (en) 1991-08-30 1996-07-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Monocyte adhesion protein and monoclonal antibody thereto
US6471965B1 (en) 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
JP4315257B2 (ja) * 1995-11-13 2009-08-19 生化学工業株式会社 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
EP0914427B1 (en) 1996-05-01 2006-03-29 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
CA2263316A1 (en) 1996-08-14 1998-02-19 Klara Berencsi Methods and compositions for preventing or retarding the development of atherosclerotic lesions
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
WO1999052551A1 (en) 1998-04-15 1999-10-21 King's College London Therapy of atherosclerosis
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100508A1 (en) * 1999-02-24 2003-05-29 Maryline Simon Carbohydrate epitope mimic compounds and uses thereof
US20030165503A1 (en) 2000-03-03 2003-09-04 Jean-Charles Fruchart Vaccine for the treatment of atherosclerosis
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0121171D0 (en) 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
GB0305794D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305790D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
GB0305793D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
US20070122419A1 (en) 2003-04-11 2007-05-31 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SE0302422D0 (sv) 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
DE602005023428D1 (de) 2004-04-15 2010-10-21 Athera Biotechnologies Ab Verfahren zur Feststellung der Gefahren von ischemischen Herzgefässerkrankungen mit PhosphorylcholinKonjugaten
US20060276400A1 (en) 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations

Also Published As

Publication number Publication date
HK1168362A1 (en) 2012-12-28
ES2656849T3 (es) 2018-02-28
PE20100808A1 (es) 2011-01-07
CA2758994A1 (en) 2010-11-11
WO2010127642A9 (es) 2011-03-24
CL2010000413A1 (es) 2011-02-25
WO2010127642A1 (es) 2010-11-11
AU2010244859B2 (en) 2014-05-29
RU2502744C2 (ru) 2013-12-27
SG175849A1 (en) 2011-12-29
EP2428521B1 (en) 2018-01-03
MX2011011665A (es) 2012-06-01
US20120121605A1 (en) 2012-05-17
AR076495A1 (es) 2011-06-15
KR20120016055A (ko) 2012-02-22
AU2010244859A1 (en) 2011-12-08
KR101374263B1 (ko) 2014-03-13
BRPI1013991A2 (pt) 2016-04-05
MY158954A (en) 2016-11-30
BRPI1013991B1 (pt) 2021-08-31
EP2428521A1 (en) 2012-03-14
JP2012526056A (ja) 2012-10-25
CN102414222B (zh) 2014-07-16
TWI424852B (zh) 2014-02-01
CN102414222A (zh) 2012-04-11
CA2758994C (en) 2015-07-21
JP5354823B2 (ja) 2013-11-27
US8470322B2 (en) 2013-06-25
TW201103559A (en) 2011-02-01
ZA201108832B (en) 2012-08-29
RU2011149252A (ru) 2013-06-10

Similar Documents

Publication Publication Date Title
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
PT2860192T (pt) Geração e perfil de anticorpos terapêuticos derivados de hucal gold totalmente humanos específicos para cd38 humana
ECSP13012609A (es) Composición farmacéutica
HRP20180230T8 (hr) Protutijela koja se vežu na protofibrile i njihova upotreba u terapijskim i dijagnostičkim postupcima kod parkinsonove bolesti, demencije s lewyjevim tijelima i drugih alfa-sinukleinopatija
MX338754B (es) Anticuerpos humanos contra el factor tisular.
CR20110509A (es) Composicion farmaceutica
CR20140394A (es) Anticuerpo monoclonal
EP2652498A4 (en) DIAGNOSIS AND TREATMENTS ASSOCIATED WITH TH2 INHIBITION
EP2307887A4 (en) MIRRORING CANCER DIAGNOSIS FROM MIRRORS OF ANTIBODIES TO GLOBO H AND TO THEIR FRAGMENTS
BRPI0911518A2 (pt) novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula
BR112015023333A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
HUE043175T2 (hu) Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
BRPI1014595A2 (pt) procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
CO6351803A2 (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
EA201692127A1 (ru) Антитела, связывающиеся с человеческим dec-205
PL2503338T3 (pl) CD73 jako biomarker do monitorowania rozwoju choroby i oceny skuteczności terapii
EA201491977A1 (ru) Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии
MY164579A (en) Safe and functional humanized antibodies
EP2041569A4 (en) ASSAY FOR DIAGNOSIS OF LUNG CANCER
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
BR112014014960A2 (pt) métodos para o diagnóstico da doença de alzheimer
CO6450654A2 (es) Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer

Legal Events

Date Code Title Description
FG Grant of patent